- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 9/08 - Vasodilators for multiple indications
Patent holdings for IPC class A61P 9/08
Total number of patents in this class: 384
10-year publication summary
|
14
|
20
|
15
|
22
|
32
|
23
|
22
|
29
|
22
|
9
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10927 |
9 |
| Nippon Shinyaku Co., Ltd. | 327 |
7 |
| Regeneron Pharmaceuticals, Inc. | 4223 |
7 |
| Daiichi Sankyo Company, Limited | 1849 |
6 |
| Mitsubishi Tanabe Pharma Corporation | 578 |
6 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3123 |
6 |
| Bayer AG | 3295 |
5 |
| Takeda Pharmaceutical Company Limited | 2703 |
5 |
| Astellas Pharma Inc. | 1085 |
5 |
| Nestec S.A. | 2680 |
4 |
| Dainippon Sumitomo Pharma Co., Ltd. | 198 |
4 |
| Kyowa Hakko Bio Co., Ltd. | 305 |
4 |
| Osaka University | 3355 |
4 |
| United Therapeutics Corporation | 305 |
4 |
| Aisa Pharma, Inc. | 16 |
4 |
| Evonik Operations GmbH | 4040 |
4 |
| Astellas Engineered Small Molecules US, Incorporated | 20 |
4 |
| Unilever PLC | 3232 |
3 |
| Unilever N.V. | 3132 |
3 |
| Ironwood Pharmaceuticals, Inc. | 162 |
3 |
| Other owners | 287 |